Drugs that contain Avibactam Sodium; Ceftazidime
1. Drug name - AVYCAZ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7112592 | ALLERGAN | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
Jan, 2026
(3 years from now) | |
| US8471025 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Aug, 2031
(8 years from now) | |
| US9284314 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| US9695122 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| US8969566 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| CN104592229A | ALLERGAN | Polymorphic Form And False Polymorphic Form Of Medicine Composition |
Aug, 2019
(3 years ago) | |
| CN1289500C | ALLERGAN | Nitrogen Heterocyclic Ring Compounds, Their Preparation Method And Their Application As Medicine, Especially Application As Antibacterial Agent |
Jul, 2021
(1 year, 2 months ago) | |
| CN1468242A | ALLERGAN | Nitrogen Heterocyclic Ring Compounds, Their Preparation Method And Their Application As Medicine, Especially Application As Antibacterial Agent |
Jul, 2021
(1 year, 2 months ago) | |
| CN102834395B | ALLERGAN | Polymorphic Form And False Polymorphic Form Of Medicine Composition |
Oct, 2030
(8 years from now) | |
| CN102834395A | ALLERGAN | Polymorphic Form And False Polymorphic Form Of Medicine Composition |
Oct, 2030
(8 years from now) | |
| CN105294690B | ALLERGAN | Preparation Comprising Anti - -7 - Oxo - -6-(Sulfo Group) -1, 6-Di-Aza-Bicyclo (3, 2, 1] -2 - Formamide Heterocyclic Compound And Its Salt Method |
Jun, 2032
(9 years from now) | |
| CN103649051B | ALLERGAN | Method For Preparing Heterocyclic Compound Comprising Reverse-7-Oxo- -6-(Sulfo Group) -1, 6-Two [3, 2, 1] -2 -Carboxamide And The Salt Thereof |
Jun, 2032
(9 years from now) | |
| CN103649051A | ALLERGAN | Method For Preparing Heterocyclic Compound Comprising Reverse-7-Oxo- -6-(Sulfo Group) -1, 6-Two [3, 2, 1] -2 -Carboxamide And The Salt Thereof |
Jun, 2032
(9 years from now) | |
| CN105294690A | ALLERGAN | The Preparation Comprises -7 - Oxo -6-(Sulfo-Oxy) -1, 6-Diazabicyclo [3 2 1] Octane - -2 - Formamide Heterocyclic Compound And Salt Thereof |
Jun, 2032
(9 years from now) | |
| IN248632B | ALLERGAN | Azabicyclic Heterocyclic Compound |
Jul, 2021
(1 year, 2 months ago) | |
| IN238630B | ALLERGAN | Process For The Preparation Of A Heterocyclic Compound |
Jul, 2021
(1 year, 2 months ago) | |
| IN200300268P1 | ALLERGAN | Azabicyclic Compounds, Preparation Thereof And Use As Medicines, In Particular As Antibacterial Agents |
Jul, 2021
(1 year, 2 months ago) | |
| IN200503239P1 | ALLERGAN | Compound Of General Formula (I) Or One Its Salts With A Base Or An Acid |
Jul, 2021
(1 year, 2 months ago) | |
| EP1307457A1 | ALLERGAN | Azabicyclic Compounds, Preparation Thereof And Use As Medicines, In Particular As Antibacterial Agents |
Jul, 2021
(1 year, 2 months ago) | |
| EP1307457B1 | ALLERGAN | Azabicyclic Compounds, Preparation Thereof And Use As Medicines, In Particular As Antibacterial Agents |
Jul, 2021
(1 year, 2 months ago) | |
| EP2486038B1 | ALLERGAN | Polymorphic And Pseudopolymorphic Forms Of A Pharmaceutical Compound |
Oct, 2030
(8 years from now) | |
| EP3269717B1 | ALLERGAN | Polymorphic And Pseudopolymorphic Forms Of Pharmaceutical Compound Nxl104 |
Oct, 2030
(8 years from now) | |
| EP3269717A1 | ALLERGAN | Polymorphic And Pseudopolymorphic Forms Of Pharmaceutical Compound Nxl104 |
Oct, 2030
(8 years from now) | |
| EP2486038A1 | ALLERGAN | Polymorphic And Pseudopolymorphic Forms Of A Pharmaceutical Compound |
Oct, 2030
(8 years from now) | |
| EP2721005B1 | ALLERGAN | Process For Preparing Heterocyclic Compounds Including Trans-7-Oxo-6-(Sulphooxy)-1,6-Diazabicyclo[3,2,1]Octane-2-Carboxamide And Salts Thereof |
Jun, 2032
(9 years from now) | |
| EP2721005A1 | ALLERGAN | Process For Preparing Heterocyclic Compounds Including Trans-7-Oxo-6-(Sulphooxy)-1,6-Diazabicyclo[3,2,1]Octane-2-Carboxamide And Salts Thereof |
Jun, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612087 | ALLERGAN | Heterocyclic compounds as inhibitors of beta-lactamases |
Nov, 2026
(4 years from now) | |
| US8835455 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Oct, 2030
(8 years from now) | |
Treatment: NA
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.5GM BASE;2GM/VIAL | POWDER;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.